Dear GEN Readers:
As we close 2025, I along with the entire GEN team want to wish all of you a happy, healthy, and successful new year. Thank you for your continuing interest in GEN’s online and print efforts to bring you critical news and information on the wide range of technologies that drive biotech R&D, biomanufacturing, and commercialization. That’s been the ongoing goal since GEN first began publishing with the January/February issue in 1981.
As biotech proceeds to evolve and grow on a global scale, you can be sure that GEN will increase its coverage of bioindustry events and developments in our core areas of artificial intelligence, bioprocessing, cancer, drug discovery, genome editing, infectious disease, OMICs, and translational medicine to keep you up to date on what you need to know to help optimize your scientific contributions in your role as an essential member of this vital industry.
GEN takes its position as a thought leader for biotech researchers and other industry professionals seriously. GEN editors ran a special section in our December issue that looked back at 2025 to highlight six of the biggest stories of the year, which not only reshaped fields, but also demonstrated the resilience and determination advancing scientific research. The titles of the stories covered in this highlights article are: FDA and Sarepta Grapple with Response to Elevidys Deaths, Baby KJ Provides a Glimpse of Tailor-Made Medicine, Boltz-2 and the Open Source Future of Drug Discovery, The Cell and Gene Therapy Rollercoaster, How NIH Budget Cuts Threaten American Science, and Eight Healthy Babies Born via Pronuclear Transfer Bring Hope for Mitochondrial Disease.
In addition to our print magazine, GEN’s journalistic mandate also includes video summits, webinars, GEN Live, and podcasts. Look for us to cast a wider news net in 2026 on Asia, Latin America, and Africa as those world regions expand their bioactivities. Also please stop and say hello to GEN editors when you see us at conferences next year and let us know about the work you and your company or organization are doing.
Feel free to contact me with anything you would like to discuss regarding GEN or biotechnology in general at [email protected]
Once again, let me wish you the best in 2026!
John Sterling, Editor-in-Chief, GEN
